
Sientra closes sale of miraDry at $10M loss
Banking & Finance, Health Care & Life Science, Latest news, South Coast, Tri-County Economy, Tri-County Public CompaniesSientra, a Goleta-based plastic surgery device company specializing in breast implants, announced June 11 that it had closed the sale of miraDry, a non-surgical dermatological treatment. The $10 million sale brought half of what Sientra paid for the business four years ago. The miraDry system is an FDA-approved treatment to reduce underarm sweat, hair and Read More →

American Riviera moves up to top OTC marketplace
Banking & Finance, Banking Industry, Latest news, South Coast, Tri-County Economy, Tri-County Public CompaniesAmerican Riviera Bank, the second-largest bank based in the Tri-Counties with nearly $1.1 billion in assets, began trading on the over-the-counter “Best Market” on June 14, a step up from its previous home on the “Pink” marketplace. Both marketplaces are run by OTC Markets Group. The Best Market, or OTCQX, is the highest tier for Read More →

Street Smarts: Bill Foley pairs Santa Barbara wine, Las Vegas hockey
Columns, Latest news, Subscriber contentThis article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Street Smarts: Ventura County follows yellow brick road to reopening
Columns, Latest news, Subscriber contentThis article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Amgen reaches billion-dollar licensing deal with Japanese firm
Banking & Finance, East Ventura County, Health Care & Life Science, Latest news, Tri-County Economy, Tri-County Public CompaniesAmgen announced an agreement June 1 with Kyowa Kirin, a Japanese pharmaceutical company, to jointly develop and commercialize a human monoclonal antibody that Kyowa Kirin is developing to treat atopic dermatitis and other autoimmune diseases. The deal could be worth $1.25 billion or more. Amgen will led the development, manufacturing and commercialization for the treatment, Read More →